+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Chronic Obstructive Pulmonary Disease Drug"

From
From
Chronic Obstructive Pulmonary Disease - Pipeline Insight, 2024 - Product Thumbnail Image

Chronic Obstructive Pulmonary Disease - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 220 Pages
  • Global
From
COPD: Update Bulletin - Product Thumbnail Image

COPD: Update Bulletin

  • Newsletter
  • April 2024
  • Global
From
From
From
Anti-Asthmatics and COPD Drugs Global Market Report 2024 - Product Thumbnail Image

Anti-Asthmatics and COPD Drugs Global Market Report 2024

  • Report
  • February 2024
  • 175 Pages
  • Global
From
From
From
Global Respiratory Drugs Market Outlook 2027 - Product Thumbnail Image

Global Respiratory Drugs Market Outlook 2027

  • Report
  • May 2020
  • 185 Pages
  • Global
From
From
From
From
Loading Indicator

Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease that affects millions of people worldwide. It is characterized by difficulty breathing, coughing, and wheezing. COPD is typically treated with a combination of medications, including bronchodilators, inhaled corticosteroids, and antibiotics. The COPD drug market is a subset of the larger respiratory drug market, which includes drugs used to treat asthma, allergies, and other respiratory conditions. The COPD drug market is highly competitive, with a variety of companies offering different types of medications. Some of the major players in the market include GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Novartis, and Merck. These companies offer a range of COPD medications, including bronchodilators, inhaled corticosteroids, and antibiotics. Other companies, such as Teva Pharmaceuticals and Mylan, also offer generic versions of these medications. Show Less Read more